LifePoint Hospitals Profits Beat Expectations Due To Higher Admissions And Health Law
In other industry news, Myriad Genetics is fighting to sustain its business model nearly two years after the Supreme Court struck down gene patents. And Modern Healthcare's first quarterly poll of top health care leaders shows most support the trend toward value-based reimbursements.
The Wall Street Journal:
LifePoint Hospitals Profit Rises On Higher Admissions
LifePoint Hospitals Inc. said on Friday that its profit rose 5% in the first quarter, as health-care reform continued to help drive higher admissions volumes. The rural hospital operator’s top and bottom lines surpassed analysts’ expectations, but the company’s shares fell about 6% in midday trading as investors focused on a deceleration in same-hospital admissions and took profits after shares rose more than 30% over the past 12 months. (Beilfuss, 5/1)
The Wall Street Journal:
Myriad Genetics Fights Off Threats From Rivals
Myriad Genetics Inc. used a patent-protected monopoly to become one of the most successful and controversial DNA testing companies in the world. Now, nearly two years after the Supreme Court struck down its gene patents, Myriad is fighting to sustain its business model amid growing threats from rivals. (Walker, 5/3)
Modern Healthcare:
CEO Power Panel Poll Finds Broad Support For Value-Based Pay
More than three-quarters of a representative sample of the nation's top healthcare leadership back the ongoing shift toward value-based payment systems, which reward providers for what they achieve rather than what they do. Yet only 20% are willing to do away completely with the industry's still dominant fee-for-service reimbursement model, according to the first quarterly poll of Modern Healthcare's CEO Power Panel. (Conn and Sandler, 5/2)
